IN THE SPOTLIGHT Paths of Resistance to EGFR Inhibitors: Is NF Enough?
نویسندگان
چکیده
Authors’ Affi liations: 1 Genetics Division, Department of Medicine, Brigham and Women’s Hospital; 2 Harvard Medical School; and 3 Ludwig Center at Dana-Farber/Harvard Cancer Center, Boston, Massachusetts Corresponding Author: Karen Cichowski, Brigham and Women’s Hospital, 77 Avenue Louis Pasteur, Genetics-NRB 0458C, Boston, MA 02115. Phone: 617-525-4722; Fax: 617-525-5801; E-mail: [email protected] .harvard.edu doi: 10.1158/2159-8290.CD-14-0286 ©2014 American Association for Cancer Research. IN THE SPOTLIGHT Paths of Resistance to EGFR Inhibitors: Is NF Enough? Ophélia Maertens 1 , 2 and Karen Cichowski 1 , 2 , 3
منابع مشابه
Paths of resistance to EGFR inhibitors: is NF enough?
Although the majority of patients with EGFR-mutant lung cancer respond well to EGF receptor (EGFR) tyrosine kinase inhibitors (TKI), all patients eventually develop resistance. The mechanism of acquired resistance is still unknown for a considerable subset of cases. This study reveals the NF1 tumor suppressor gene as a new mediator of resistance to EGFR TKIs and provides a mechanistic rationale...
متن کاملEvaluation of cytotoxicity mechanism of two cyclo-oxygenase-2 inhibitors in leukemia cell line
Introduction: Leukemia is considered one of the main causes of death, and current chemotherapeutic agents are unable to provide optimal responses due to chemo-resistance. Therefore, there is a constant need for new drugs. Cyclooxygenase- 2 (COX-2) inhibitors can be helpful by reducing the necessary dose of routine chemotherapeutic drugs. Herein, we evaluated the cytotoxicity activity as well...
متن کاملNF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor
The clinical efficacy of EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations is limited by the emergence of acquired resistance, mostly ascribed to the secondary EGFR-T790M mutation. Selective EGFR-T790M inhibitors have been proposed as a new, extremely relevant therapeutic approach. Here, we demonstrate that the novel irreversible E...
متن کاملAcquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC
Epithelial-mesenchymal transition (EMT) is clinically associated with acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in non-small cell lung cancers (NSCLC). However, the mechanisms promoting EMT in EGFR TKI-resistant NSCLC have not been fully elucidated. Previous studies have suggested that IGF1R signaling is involved in both acquired EGFR TKI re...
متن کاملPI3K and mTOR inhibitor, NVP-BEZ235, is more toxic than X-rays in prostate cancer cells
Background: Radiotherapy and adjuvant androgen deprivation therapy have historically been the first treatment choices for prostate cancer but treatment resistance often limits the capacity to effectively manage the disease. Therefore, alternative therapeutic approaches are needed. Here, the efficacies of radiotherapy and targeting the pro-survival cell signaling components epidermal growth fact...
متن کامل